Scientific Events

Scientific Events
Nov 16, 2018 at 10:00 AM EST
Poster Title:                “Harnessing the anticancer activity of the stapled peptide ALRN-6924, a dual inhibitor of MDMX and MDM2, using rational combination strategies for breast cancer and other malignancies”
Session Name:            Molecular Targeted Agents - PART II
Session Date:              November 16th, 10:00 a.m.-2:00 p.m. local time
Location:                     The Convention Centre Dublin, Exhibition Hall
Nov 9, 2018 at 8:00 AM EST
Poster Title:                The stapled peptide ALRN-6924, a dual inhibitor of MDMX and MDM2, displays immunomodulatory activity and enhances immune checkpoint blockade in syngeneic mouse models” 
Session Date:              Nov. 9th, 8 a.m.– 8 p.m. and Nov. 10th, 8 a.m.– 8:30 p.m. local time
Location:                     Walter E. Washington Convention Center, Hall E
Apr 11, 2018 at 12:00 PM EDT

Luis A. Carvajal1, Daniela Ben Neriah1, Adrien Senecal2, Lumie Benard1, Victor Thiruthuvanathan1, Tatyana Yatsenko1, Swathi-Rao Narayanagari1,3, Justin C. Wheat1, Tihomira I. Todorova1, Kelly Mitchell1, Charles Kenworthy2, Vincent Guerlavais4, D. Allen Annis4, Boris Bartholdy1, Britta Will1,3,5,6, Jesus D. Anampa5, Ioannis Mantzaris5, Manuel Aivado4, Robert H. Singer2, Robert A. Coleman2, Amit Verma3,5,6 and Ulrich Steidl1,3,5,6,*

1Department of Cell Biology, Albert Einstein College of Medicine, Bronx, NY 10461, USA.
2Department of Anatomy and Structural Biology, Albert Einstein College of Medicine, Bronx, NY 10461, USA.
3Ruth L. and David S. Gottesman Institute for Stem Cell Research and Regenerative Medicine, Albert Einstein College of Medicine, Bronx, NY 10461, USA.
4Aileron Therapeutics, Cambridge, MA 02139, USA.
5Division of Hemato-Oncology, Department of Medicine (Oncology), Albert Einstein College of Medicine, Bronx, NY 10461, USA.
6Albert Einstein Cancer Center, Albert Einstein College of Medicine, Bronx, NY 10461, USA.
↵*Corresponding author. Email: ulrich.steidl@einstein.yu.edu
Hide authors and affiliations

Science Translational Medicine  11 Apr 2018:
Vol. 10, Issue 436, eaao3003
DOI: 10.1126/scitranslmed.aao3003

Abstract: http://stm.sciencemag.org/cgi/content/abstract/10/436/eaao3003?ijkey=SDWKRypaJhAlk&keytype=ref&siteid=scitransmed

Reprint: http://stm.sciencemag.org/cgi/rapidpdf/10/436/eaao3003?ijkey=SDWKRypaJhAlk&keytype=ref&siteid=scitransmed

Full Text: http://stm.sciencemag.org/cgi/content/full/10/436/eaao3003?ijkey=SDWKRypaJhAlk&keytype=ref&siteid=scitransmed

Dec 11, 2017 at 7:00 AM EST

Presentation Title:In Vitro and Preclinical In Vivo Evidence Support MDMX/MDM2 as Common Vulnerabilities Across TP53-Wild-Type T-Cell Lymphomas That Are Targetable with the Alpha-Helical P53 Stapled Peptide ALRN-6924”
Session Name: 625. Lymphoma: Pre-Clinical—Chemotherapy and Biologic Agents: Novel Targeted therapies for Non-Hodgkin's Lymphomas
Session Date: Monday, December 11, 2017
Session Time: 7:00 a.m. - 8:30 a.m. EST
Presentation Time: 7:00 a.m. EST

Presentation Title“Dual Inhibition of MDMX and MDM2 Using an Alpha-Helical P53 Stapled Peptide (ALRN-6924) As a Novel Therapeutic Strategy in Acute Myeloid Leukemia”
Session Name: 604. Molecular Pharmacology and Drug Resistance in Myeloid Diseases: Novel Therapeutics and Mechanisms of Resistance in Myeloid Disease
Session Date: Monday, December 11, 2017
Session Time: 4:30 p.m. – 6:00 p.m. EST
Presentation Time: 5:00 p.m. EST

Jun 3, 2017 at 3:39 PM EDT

Oral Abstract Session: “Phase I trial of a novel stapled peptide ALRN-6924 disrupting MDMX- and MDM2-mediated inhibition of WT p53 in patients with solid tumors and lymphomas”
Session Title: Developmental Therapeutics—Clinical Pharmacology and Experimental Therapeutics

Abstract #:2505

VIEW ABSTRACT
VIEW PRESENTATION